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AbsTrACT
Objective approximately 35% of patients with 
amyotrophic lateral sclerosis (aLs) exhibit mild cognitive 
deficits in executive functions, language and fluency, 
without dementia. The precise pathology of these 
extramotor symptoms has remained unknown. This 
study aimed to determine the pathological correlate of 
cognitive impairment in patients with non-demented aLs.
Methods In-depth neuropathological analysis of 27 
patients with non-demented aLs who had undergone 
cognitive testing (edinburgh cognitive and Behaviour 
aLs screen (ecas)) during life. analysis involved 
assessing 43 kDa Tar-DNa binding protein (TDp-43) 
accumulation in brain regions specifically involved in 
executive functions, language functions and verbal 
fluency to ascertain whether functional deficits would 
relate to a specific regional distribution of pathology.
results all patients with cognitive impairment 
had TDp-43 pathology in extramotor brain regions 
(positive predictive value of 100%). The ecas also 
predicted TDp-43 pathology with 100% specificity in 
brain regions associated with executive, language and 
fluency domains. We also detected a subgroup with no 
cognitive dysfunction, despite having substantial TDp-43 
pathology, so called mismatch cases.
Conclusions cognitive impairment as detected by 
the ecas is a valid predictor of TDp-43 pathology in 
non-demented aLs. The profile of mild cognitive deficits 
specifically predicts regional cerebral involvement. These 
findings highlight the utility of the ecas in accurately 
assessing the pathological burden of disease.
INTrOduCTION
Amyotrophic lateral sclerosis (ALS) has a heteroge-
neous clinical manifestation and is accompanied by 
cognitive and/or behaviour dysfunction in 35% of 
patients, with an additional 15% exhibiting a fron-
totemporal dementia (FTD) typically a behavioural 
variant.1–3 Patients show executive dysfunction, 
social cognition, language and letter fluency defi-
cits, in addition to abnormal behaviour, notably 
apathy.1 These extramotor symptoms are associ-
ated with reduced survival. However, their precise 
pathology has remained unknown.
The presence of 43 kDa Tar-DNA binding protein 
(TDP-43), whose pathological misfolding and accu-
mulation is observed in the brains and spinal cord 
of patients with ALS, except for cases of superoxide 
dismutase 1 (SOD1) mutation, suggests a common 
underlying process.4 TDP-43 is a predominantly 
nuclear protein involved in transcriptional regula-
tion. In ALS, TDP-43 is pathologically phosphor-
ylated and C-terminally truncated in cytoplasmic 
aggregates.5 The toxicity may be partly loss and 
partly gain-of-function: insoluble aggregates inhibit 
TDP-43 function in transcriptional regulation, 
while cytoplasmic aggregates can lead to the dysreg-
ulation of proteostasis and sequester other aggre-
gation prone proteins, causing further cytotoxicity 
and contributing to cell death.6 7
In ALS brains, TDP-43 pathology can be widespread 
in cases of ALS-related/FTD and some have suggested 
a sequential spread.8 A non-specific association was 
found between the presence of cognitive impairment 
(yes/no) as measured by a dementia screening tool, 
the Mini Mental State Examination and moderate 
to severe TDP-43 pathology.9 Using more detailed 
neuropsychology, Prudlo and colleagues divided the 
patients with ALS into three clinical groups: ALS 
with no cognitive impairment, ALS with cognitive 
impairment and ALS-FTD. A significant difference 
was demonstrated in the severity of pathologically 
misfolded TDP-43 inclusions, between patients with 
ALS-FTD and the combined non-demented clinical 
groups (ALS with or without cognitive impairment); 
however, there was no difference between the two 
non-demented groups: ALS with cognitive impair-
ment and ALS with no cognitive impairment.10 An 
association between the cognitive profile in patients 
with non-demented ALS with cognitive impairment 
and TDP-43 has not been shown previously. Further-
more, the association between specific cognitive func-
tions (executive, language and fluency) tested during 
life using the same cognitive tool and the distribu-
tion of postmortem TDP-43 pathology over several 
distinct brain regions has never been demonstrated. 
Studies are limited as cohorts have been assessed 
by different cognitive tests not designed for ALS or 
physical disability. The introduction of, the Edin-
burgh Cognitive and Behavioural ALS Screen (ECAS) 
enables a more cohesive approach. This standardised 
tool assesses ALS-related cognitive deficits (verbal 
fluency, executive and language functions) and is 
sensitive to milder cognitive impairments.1 11 Using 
the ECAS, we have been able to demonstrate an asso-
ciation between the presence of cognitive impairment 
and synaptic loss in the prefrontal cortex of patients 
with ALS.7 Here we are the first to examine the rela-
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Table 1 Functional and clinical correlates of chosen brain regions 
identified a priori for analysis
brodmann area Functional correlate Clinical correlate
BA6, BA11, BA24, BA46 Executive ECAS (ALS specific 
subtests and scores)BA9, BA44, BA41 Fluency
BA20, BA39 Language





ALS, amyotrophic lateral sclerosis; ECAS, Edinburgh Cognitive and Behavioural ALS 
Screen.
as detected by the ECAS in non-demented ALS and the localised 
distribution of TDP-43.
The aim was to determine the pathological correlate of cognitive 
impairment in patients with non-demented ALS. Our hypotheses 
are that (1) the specific profile of cognitive impairment in patients 
with non-demented ALS (executive, fluency and language dysfunc-
tion) is associated with TDP-43 pathology in corresponding brain 
regions identified a priori and (2) the ECAS assessed in vivo is a 
good predictor of TDP-43 pathology postmortem.
MeThOds
Case identification
We identified, from the Medical Research Council (MRC) Edin-
burgh Brain Bank, 27 ALS cases who had undergone neuropsy-
chological testing with the ECAS during life. Additionally, all cases 
had separately undergone whole genome sequencing. All clinical 
data including the ECAS were collected as part of Scottish Motor 
Neuron Disease Register (SMNDR) and Care Audit Research and 
Evaluation for Motor Neuron Disease (CARE-MND) platform 
and all patients consented to the use of their data during life. All 
postmortem tissue was collected via the Edinburgh Brain Bank in 
line with the Human Tissue (Scotland) Act.
Cognitive assessment
Cognitive impairment was measured using the ECAS, and all 
assessments were performed according to the standard proce-
dure (https:// ecas. psy. ed. ac. uk/). The ECAS is specifically 
designed to assess the profile of cognitive impairment in ALS 
and is adapted for patients with physical disability. It consists of 
16 subtests across five cognitive domains: executive functions, 
language functions and letter fluency which combine to produce 
and ALS-specific score, while memory and visuospatial functions 
combine to produce an ALS-non-specific score. The ECAS also 
includes a carer behavioural interview based on criteria for diag-
nosing behavioural variant FTD.2
The ECAS provides high sensitivity and specificity in the 
detection of mild cognitive deficits in ALS against gold standard 
neuropsychological assessment using published cut-off scores for 
abnormality; has been validated extensively in many different 
diverse populations of patients with ALS and against other 
neuropsychological screening tools and batteries.3 12–19
The final ECAS score (maximum score of 136) is made up of 
the ALS-specific (maximum score of 100) and ALS-non-specific 
(maximum score of 36) scores. A person can be judged to be 
cognitively impaired (ALSci) if they have failed the ECAS (see 
supplemental information for diagnosing ALS-frontotemporal 
spectrum disorder using the ECAS). Here we used published 
cut-offs for the ECAS total and ALS-specific scores which have 
shown maximum sensitivity and specificity to detect ALS-re-
lated cognitive impairment against extensive neuropsycholog-
ical assessment.12 The cut-offs for abnormality are ECAS Total 
105/136 or less, ALS-specific score 77/100 or less. Abnormality 
cut-off scores for the cognitive subdomains are 33/48 for exec-
utive function, 14/24 for fluency and 26/28 for language func-
tion.3 ALS with behavioural impairment (ALSbi) was defined 
as the presence of apathy or two other behaviour features as 
defined by the consensus.2
histology and neuropathological assessment
Brain tissue was taken at postmortem from standardised Brodmann 
areas (BA) and fixed in 10% formalin for a minimum of 24 hours. 
Tissue was dehydrated in an ascending alcohol series (70%–100%) 
followed by three successive 4-hour washes in xylene. Three 
successive 5-hour paraffin wax embedding stages were performed 
followed by cooling and sectioning of the formalin-fixed paraffin 
embedded (FFPE) tissue on a Leica microtome in 4 µm sections 
on to a superfrost microscope slide. Sections were dried overnight 
at 40°C and immunostaining was performed using the Novolink 
Polymer detection system with the Proteintech anti-phospho(409-
410)-TDP-43 antibody at a 1 in 1000 dilution and 3,3′-diamino-
benzidine chromogen and counterstained with haematoxylin, 
according to standard operating procedures.
For the purpose of later analyses, regions of the brain were 
grouped according to their association with (1) executive, (2) 
language functions or (3) letter fluency based on functional 
imaging and pathological studies.20–22 Brain regions which have 
been previously associated with executive functions included the 
orbitofrontal cortex (BA11/12), ventral anterior cingulate (BA24), 
dorsolateral prefrontal cortex (BA46 and BA9) and the medial 
prefrontal cortex (BA6). Regions associated with language func-
tions included the inferior frontal gyrus (Broca’s area; BA44/45), 
transverse temporal area (Heschl’s gyri; BA41/42), middle and 
inferior temporal gyri (BA20/21) and the angular gyrus (BA39). 
In accordance with the underlying cognitive processes involved 
in fluency regions associated with fluency overlap between those 
of executive and language functions including the prefrontal 
cortex (BA9), inferior frontal gyrus (Broca’s area; BA44/45), 
ventral anterior cingulate (BA24) and the transverse temporal 
area (Heschl’s gyri; BA41/42). For a summary of these regions, 
see table 1. TDP-43 pathology was graded by two independent 
pathologists (pretest reviewer concordance acceptability was set 
at >0.66; therefore, disagreements were solved by discussion, 
resulting in 100% concordance), using a semiquantitative scoring 
system from 0 to 3: 0=no TDP-43 pathology; 1=mild (up to 
five affected cells in at least one 20× field of view per section); 
2=moderate (5–15 affected cells in at least one 20× field of view 
per section); 3=severe (>15 cells affected in at least one 20× 
field of view per section) (figure 1A). Cases defined as having 
no pathology had a score of 0, while those with pathology had 
a score from 1 to 3 for each region. This scoring was applied to 
neuronal and glial cell population (based on established neuro-
pathological knowledge of cell morphology using haematoxylin 
counterstain). Neuronal cells were determined by their larger 
cell size (nucleus surrounded by a large volume of cytoplasm, 
the presence of dendrites and cortical layer location). Glia were 
designated based on small cell size with oval to round nuclei 
with compact chromatin, small rim of cytoplasm. Assessors were 
blinded to all demographic and clinical information. Regions 
grouped by their functional significance had to have three out 
of four (or two out of three for fluency) regions with TDP-43 
pathology present to be classified as positive for pathology and 
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Figure 1 subdomain cognitive dysfunction detected by the ecas relates 
to specific regional distribution of TDp-43 pathology. (a) pathological 
TDp-43 staining, demonstrating characteristic cytoplasmic aggregation 
and nuclear clearance of TDp-43. Images are taken at 20× magnification, 
illustrating mild, moderate and severe scoring of pathology. (B) sensitivity 
and specificity analysis assessing the utility of ecas subdomains in 
predicting TDp-43 pathology in corresponding brain regions, demonstrating 
high positive predictive value. Values are percentage with 95% cIs. ecas, 
edinburgh cognitive and Behavioural amytrophic lateral sclerosis screen.
Figure 2 cell-type specific TDp-43 pathology differs between individuals. 
pathological TDp-43 staining, demonstrating (a) predominantly glial 
inclusions; (B) mixed glial and neuronal inclusions and (c) predominantly 
neuronal inclusions. Images are taken at 20× magnification; red arrows 
indicate neurons and blue arrows indicate glial cells. (D) Frequency 
distribution demonstrating the number of cases with each of these 
characteristic cell-type specific inclusions. each column is subdivided into 
red (evidence of cognitive dysfunction) and blue (no evidence of cognitive 
dysfunction) showing that there is no apparent link between cell-type 
specific TDp-43 accumulation and cognitive dysfunction in the cases that 
we analysed. aLs, amyotrophic lateral sclerosis; TDp-43, 43 kDa Tar-DNa 
binding protein.
statistical methods
Sensitivity, specificity, positive and negative predictive values are 
expressed as percentages. CIs for sensitivity and specificity are 
exact Clopper-Pearson CIs. CIs for the likelihood ratios are calcu-
lated using the Log method. CIs for the predictive values are the 
standard logit CIs. GraphPad Prism V.5.0 was used to present 
graphical data. Non-parametric analysis of (1) median survival 
was performed using Mann-Whitney U test and (2) time between 
ECAS testing and death was performed using two-tailed Fisher’s 
exact text. Shapiro-Wilk test was performed to ensure data were 
normally distributed. One-way analysis of variance (ANOVA) was 
used to compare cognitively impaired and unimpaired cases with 
different cell-type specific distributions of TDP-43 (figure 2D).
resulTs
Cohort demographics
Twenty-seven patients with ALS (clinically established by El Esco-
rial criteria) from the Edinburgh Brain Bank who had undergone 
neuropsychological testing during life using the ECAS were iden-
tified (table 2). No patient had a diagnosis of dementia in their 
clinical notes. All the patients had undergone whole genome 
sequencing identifying nine individuals with a confirmed genetic 
ALS-associated mutation, with five C9orf72 cases, two cases 
carrying the SOD1 (I114T) Scottish founder mutation and two 
cases with mutations of uncertain significance in the NEK1 gene.23 
Seventy-two per cent of cases identified had limb onset disease, 
23% had bulbar onset disease and one individual had a combined 
limb and bulbar onset of disease. Seven individuals (26% of the 
cohort) were classified as having ALSci (see table 3). Behavioural 
data was available on nine cases of which three were classified 
as ALSbi, one of which carried the I114T SOD1 mutation. No 
individual showed ALScibi, likely reflecting the small number of 
individuals with available behavioural data (nine individuals within 
the cohort). Eleven individuals demonstrated cognitive impair-
ment in specific subdomains; executive function only (one indi-
vidual), language (six individuals) and fluency (two individuals) 
with two individuals having a mixed deficit affecting all three 
domains (table 3). Only one case with language dysfunction was 
also impaired on the memory subtest, but none were impaired on 
visuospatial testing.
Cognitive dysfunction detected by the eCAs is associated 
with pathological TdP-43 accumulation
To determine whether cognitive impairment as detected by the 
ECAS was a good predictor of extramotor pathology in ALS we 
first assessed whether patients with impaired ECAS scores exhib-
ited extramotor pathology assessed by TDP-43 aggregation in 
postmortem tissue.
Three out of 27 patients met criteria for ALSbi; one of these 
had a NEK1 mutation, one had a SOD1 mutation and one was 
a sporadic case. The brain areas thought to predominantly be 
associated with behavioural dysfunction are (1) the orbitofrontal 
cortex (BA11/12), (2) ventral anterior cingulate (BA24) and (3) 
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Table 2 ECAS cohort demographics
demographics n (%) Median (months) IQr (months)
Age
  At disease onset 56 48–60.75
  At death 63 50.25–66
Disease duration 31.5–98.75
Sex
  Male 12 (45)
  Female 15 (55)
Disease onset
  Upper limb 8 (36)
  Lower limb 8 (36)
  Bulbar 5 (23)
  Combined 1 (5)
Genetic diagnosis
  C9orf72 6 (23)
  SOD1 (I114T) 2 (9)
  NEK1 2 (9)
  No known mutation (all had WGS) 17 (59)
Cognitive impairment (ECAS) 11 (40)
  Executive dysfunction 1 (4)
  Language 6 (22)
  Fluency 2 (7)
  Combined 2 (7)
Summary of clinical findings and demographics of patient cohort.
ECAS, Edinburgh Cognitive and Behavioural Amyotrophic lateral sclerosis Screen; 
WGS, whole-genome sequencing.
in the case with SOD1 mutation, in keeping with previous 
literature; however, the remaining two cases did have TDP-43 
inclusions in two or more of these brain regions (table 4). 7 
out of our cohort of 27 patients met criteria for ALSci. All 7 of 
these patients exhibited TDP-43 pathology in extramotor brain 
regions (table 4). Therefore, in every case exhibiting ALSci, there 
was evidence of extramotor TDP-43 pathology. There were six 
false negatives, whereby TDP-43 pathology in extramotor brain 
regions was not accompanied by an impairment in the ECAS.24 
These data taken together were used to assess the diagnostic 
accuracy of ECAS in predicting TDP-43 pathology in extramotor 
brain regions resulting in a diagnostic accuracy of 66.67% (95% 
CI 46.04 to 83.48), with a sensitivity of 43.75% (95% CI 19.75 
to 70.12) and a specificity of 100% (95% CI 71.51 to 100).
subdomain cognitive dysfunction detected by the eCAs 
relates to specific regional distribution of pathology
Three of the 27 patients demonstrated mild executive dysfunc-
tion when tested (one with pure executive dysfunction and two 
with a combined executive, language and fluency dysfunction) 
and all three had corresponding TDP-43 pathology at post-
mortem in the brain areas associated with executive functions 
(BA6, BA11, BA24, BA46 and BA9). Furthermore eight of the 27 
patients demonstrated mild language impairment (BA44, BA41, 
BA20 and BA39) when tested with ECAS (six with pure language 
dysfunction and two with a combined executive, language 
and fluency dysfunction), all of whom had TDP-43 pathology 
in corresponding brain areas at postmortem. Four of the 27 
patients demonstrated mild fluency dysfunction when tested 
with ECAS (two with pure fluency dysfunction and two with 
a combined executive, language and fluency dysfunction) and 
all four had corresponding TDP-43 pathology at postmortem in 
the brain areas associated with fluency (BA9, BA44 and BA41). 
There were no cases where cognitive impairment was present in 
the absence of TDP-43 pathology; however, there was a small 
subgroup (n=6) of patients who had TDP-43 pathology with 
no cognitive impairment (false negatives). These results taken 
together gave rise to the ECAS accurately predicting TDP-43 
pathology with a positive predictive value of 100% and 100% 
specificity in executive function, language and fluency domains 
(figure 1B).
GeNeTIC sTATus, COGNITIve IMPAIrMeNT ANd 
PAThOlOGy
Six out of the 27 cases identified had a genetic diagnosis of a 
C9orf72 repeat expansion; all cases had extramotor TDP-43 
pathology at postmortem, irrespective of cognitive impairment. 
This is in stark contrast to two patients in the cohort with a 
SOD1 (I114T) mutation (Scottish founder mutation), who had 
no detectable TDP-43 pathology and no cognitive dysfunction 
(although one additional SOD1 individual was classified as 
ALSbi, but had no TDP-43 pathology), consistent with previous 
neuropathological and neuropsychological assessments.9 25 
Of these six C9orf72 repeat expansion cases, one had execu-
tive dysfunction and three had language impairment. We also 
identified two patients carrying a NEK1 mutation, one of these 
patients had ALSbi with TDP-43 pathology and the other had no 
cognitive impairment and no evidence of extramotor TDP-43 
pathology at postmortem.
TdP-43 protein distribution is cell-type specific and differs 
between individuals
Analysis of the cell-type specific distribution of TDP-43 
pathology was performed demonstrating three predominating 
patterns: (1) predominantly glial (22.2% of cases), (2) mixed 
glial and neuronal (59.3% of cases) and (3) predominantly 
neuronal TDP-43 pathology (7.4% of cases; figure 2). One-way 
ANOVA was performed to assess whether the cell-type specific 
distribution of TDP-43 pathology was associated with cognition 
in the regions assessed (figure 2D), demonstrating no significant 
difference (p>0.05; table 5). Indeed, there was no statistically 
significant difference between the groups for other demographic 
and clinical characteristics, including sex, anatomical onset of 
disease, median age at onset or death, disease duration or genetics 
(measured by one-way ANOVA with Bonferroni correction for 
multiple testing p>0.05; table 5). This is likely due to the small 
sample size evaluated and clearly warrants further investigation 
in a larger cohort or meta-analysis of existing data to evaluate 
conclusively whether these phenotypes impact on clinical char-
acteristics of ALS and or FTD.
dIsCussION
We undertook an in-depth neuropathological analysis of 27 
patients with non-demented ALS who had all undergone cogni-
tive testing with the ECAS during life and demonstrated that 
all individuals with ALS-specific cognitive deficits (ALSci) had 
TDP-43 pathology in extramotor areas. Furthermore, a more 
detailed analysis of the types of cognitive impairment (executive/
language/fluency) revealed a direct association between TDP-43 
pathology and specific corresponding brain regions of the 
frontal and temporal lobes. Specifically we showed that (1) exec-
utive dysfunction was associated with TDP-43 pathology in the 
following regions: the orbitofrontal cortex (BA11/12), ventral 
anterior cingulate (BA24), dorsolateral prefrontal cortex (BA46 
and BA9) and the medial prefrontal cortex (BA6); (2) language 
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eCAs total executive language Fluency Memory visuospatial behaviour
Case 1 N 92 33 125 42 28 22 22 11 4
Case 2 (NEK1) N 86 30 116 38 28 20 18 12 2
Case 3 (SOD1) N 87 31 118 41 28 18 19 12 2
Executive dysfunction Cognitive assessment






eCAs total executive language Fluency Memory visuospatial behaviour
Case 4 
(C9orf72)










eCAs total executive language Fluency Memory visuospatial behaviour
Case 5 
(C9orf72)
N 85 27 112 39 26 20 15 12 0
Case 6 
(C9orf72)
Y 76 26 102 35 23 18 14 12 ND
Case 7 Y 81 20 101 37 26 18 8 12 ND
Case 8 
(C9orf72)
Y 74 26 100 36 20 18 14 12 ND
Case 9 N 88 26 114 44 26 18 14 12 ND
Case 10 N 85 26 111 36 25 24 14 12 0
Fluency dysfunction Cognitive assessment






eCAs total executive language Fluency Memory visuospatial behaviour
Case 11 Y 75 30 105 39 28 8 18 12 ND
Case 12 N 82 33 115 44 28 10 21 12 ND
Combined deficit: executive, 
language and fluency
Cognitive assessment






eCAs total executive language Fluency Memory visuospatial behaviour
Case 13 Y 65 26 91 32 25 8 15 11 0
Case 14 Y 62 28 90 32 22 8 16 12 ND
Unimpaired Cognitive assessment






eCAs total executive language Fluency Memory visuospatial behaviour
Case 15 
(C9orf72)
N 83 31 114 39 28 16 21 10 0
Case 16 N 87 33 120 41 28 18 21 12 ND
Case 17 N 97 35 132 47 28 22 23 12 ND
Case 18 N 93 32 125 45 28 20 20 12 1
Case 19 (NEK1) N 88 30 118 42 28 18 18 12 ND
Case 20 N 85 29 114 39 28 18 17 12 ND
Case 21 N 86 30 116 40 28 18 18 12 ND
Case 22 N 82 33 115 35 27 20 21 12 0
Case 
23(C9orf72)
N 86 32 118 40 28 18 20 12 0
Case 24 N 83 29 112 38 27 18 17 12 ND
Case 25 N 82 29 111 36 28 18 17 12 ND
Case 26(SOD1) N 82 28 110 34 28 20 16 12 ND
Case 27 N 92 32 124 44 28 20 20 12 ND
Summary of ECAS scores for each patient in the cohort, subdivided by subdomain deficits.
ALS, amyotrophic lateral sclerosis; ALSci, cognitively impaired ALS; ECAS, Edinburgh Cognitive and Behavioural ALS Screen; ND, not done.
frontal gyrus (Broca’s area; BA44/45), transverse temporal area 
(Heschl’s gyri; BA41/42), middle and inferior temporal gyri 
(BA20/21) and the angular gyrus (BA39); (3) fluency dysfunc-
tion was associated with TDP-43 pathology in the prefrontal 
cortex (BA9), inferior frontal gyrus (Broca’s area; BA44/45), 
ventral anterior cingulate (BA24) and the transverse temporal 
area (Heschl’s gyri; BA41/42) and (4) behavioural impairment 
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Table 5 Cell-type specific pathology in ALS
TdP-43 pathology Glial Mixed Neuronal sOd1/no TdP-43 pathology
Number of patients 6 16 2 3
Proportion of cohort 22.2 59.3 7.4 11.1
Sex (M/F) 4 M; 2 F 9 M; 7 F 1 M; 1 F 2 F; 1 M
Onset
  Limb 3 13 2 3
  Bulbar 3 2 0 0
  Both 0 1 0 0
Median age (range)
  At disease onset 56 (39–69) 56 (45–79) 60 (54–66) 45 (32–59)
  At death 63 (43–70) 63 (50–84) 69 (62–76) 48 (40–64)
Median disease duration 58 (16–109) 43 (13–134) 108 (97–199) 67 (30–98)
Genetics
  No mutation 3 13 0 1
  C9orf72 3 2 1 0
  SOD1 0 0 0 2
  NEK1 0 1 1 0
Impaired cognition (ECAS)
  Behavioural 0 2 0 1
  Executive 0 0 1 0
  Language 2 4 0 0
  Fluency 1 1 0 0
  Combined 0 2 0 0
Summary of clinical findings and demographics of cohort separated by cell-type specific TDP-43 pathology (as demonstrated in figure 2).
ALS, amyotrophic lateral sclerosis; ECAS, Edinburgh Cognitive and Behavioural ALS Screen; F, female; M, male; TDP-43, 43 kDa Tar-DNA binding protein.
cortex (BA11/12), ventral anterior cingulate (BA24) and medial 
prefrontal cortex (BA6). We recognise that a potential limita-
tion of these data is the difference in time between ECAS testing 
during life and time of death. However, we demonstrate that 
there was no effect of time between ECAS and death on our 
data. As such we are confident that our conclusions from these 
data are robust and meaningful.
Staging of TDP-43 pathology at postmortem has been 
described previously and together with the current findings indi-
cates that the pathological accumulation of TDP-43 is clearly 
related to the clinical manifestations of ALS and could be a prom-
ising biomarker.9 26 We chose to assess TDP-43 pathology using 
a semiquantitative scoring system to assess non-motor brain 
regions, rather than the scoring systems previously published 
by Brettschneider and colleagues which focused on the motor 
region and behavioural variant FTD.9 27 Using our system, we 
were able to assess abundance of TDP-43 pathology in specific 
brain regions associated with subdomains of the ECAS and also 
to identify cell-type specific patterns of TDP-43 pathology, 
allowing us to generate a specific data set relevant to cognitive 
testing. Here, we present the first evidence suggesting that ECAS 
could be used to accurately predict the presence of TDP-43 
pathology in specific non-motor brain regions at post-mortem. 
Indeed, the ECAS is now used worldwide in ALS clinics (https:// 
ecas. psy. ed. ac. uk), highlighting the potential impact and clinical 
utility of these findings. Cognitive changes are found in about 
half of cases of ALS and given that these clinical manifestations 
of the disease are likely related to TDP-43 accumulation, there 
is potential for targeted therapies to improve cognition aimed at 
reducing the burden of misfolded TDP-43. These findings raise 
the possibility of using ECAS as a stratification tool in clinical 
trials, aimed at reducing cognitive symptoms in at risk individ-
uals. Given that no false positives would be identified, the use 
of the ECAS as a stratification tool would not result in anyone 
being incorrectly included in such a clinical trial.
Although there were some cases with mild involvement of 
BA19 (five cases) and hippocampal pathology (four cases), there 
was no associated functional (memory, visuospatial) impairment. 
We identified one case with language impairment that also had 
some mild BA19 pathology. In this case, there was no addi-
tional hippocampal pathology and it is therefore likely that they 
performed poorly on the story recall memory test due to other 
cognitive problems (eg, language) and not because a primary 
impairment in memory.
There were three predominating cell-type specific patterns of 
TDP-43 pathology: (1) predominantly glial (22.2% of cases); 
(2) mixed neuronal and glial (59.3% of cases) and (3) predomi-
nantly neuronal (7.4% of cases). This finding is clearly present in 
other published pathological data sets28 and images,29 however, 
has, to our knowledge, never been formally reported. While our 
data showed no statistically significant association with cogni-
tion in these brain regions, we do not have an adequate sample 
size to be able to comment more specifically on the implica-
tions of this finding on ALS pathogenesis. However, given that 
this cell-type specific distribution of TDP-43 pathology exists, 
it is crucial that animal and cell models accurately model these 
differing neuronal and glial pathologies in future experimental 
paradigms. There is a focus on neuronal models of ALS, which 
may not accurately model the 22.2% of cases that we found to 
have a predominantly glial pattern of TDP-43 pathology.
Furthermore, in line with previous neuropathological studies 
of patients with ALS, all C9orf72 repeat expansion carrying 
patients and none of the patients with a SOD1 mutation had 
TDP-43 pathology at postmortem and neither TDP-43 severity 
nor cell-type distribution was associated with disease progres-
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TDP-43 pathology at postmortem: (1) cognitive dysfunction 
assessed by the ECAS and (2) C9orf72/SOD1 status. Given the 
impact that cognition has on the quality of life of both patients 
and carers, future studies looking at the effects of therapies, 
targeting protein misfolding, on cognitive function in patients 
with ALS, independent of their effects on survival or motor 
function, are clearly warranted. Our data demonstrate the utility 
of the ECAS in predicting TDP-43 pathology in extra-motor 
brain regions in postmortem tissue. The primary advantage of 
a specificity of 100% is that no individual would be incorrectly 
included in a clinical trial aimed at reducing TDP-43 burden. 
However, the major limitation to this is the lower sensitivity 
of the ECAS in predicting this burden of pathology, meaning 
that some patients, who could plausibly benefit from such a 
trial, would not be identified. However, recently we identified a 
striking difference in spatial expression of a pathological marker 
called clusterin in mismatch cases that would not be identified 
by the ECAS.24 It is therefore plausible that biomarkers exist 
that could be developed to enable improved sensitivity to iden-
tify further individuals that may be missed by the ECAS testing. 
Crucially the ECAS may therefore have ever improving utility in 
(1) identifying patients for inclusion and (2) monitoring patients’ 
response to treatment, in clinical trials aimed at reducing patho-
logical TDP-43 accumulation.
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